Trichostatin A for Efficient CRISPR-Cas9 Gene Editing of Human Pluripotent Stem Cells
Overview
Affiliations
Genome-edited human-induced pluripotent stem cells (iPSCs) have broad applications in disease modeling, drug discovery, and regenerative medicine. Despite the development of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system, the gene editing process is inefficient and can take several weeks to months to generate edited iPSC clones. We developed a strategy to improve the efficiency of the iPSC gene editing process via application of a small-molecule, trichostatin A (TSA), a Class I and II histone deacetylase inhibitor. We observed that TSA decreased global chromatin condensation and further resulted in increased gene-editing efficiency of iPSCs by twofold to fourfold while concurrently ensuring no increased off-target effects. The edited iPSCs could be clonally expanded while maintaining genomic integrity and pluripotency. The rapid generation of therapeutically relevant gene-edited iPSCs could be enabled by these findings.
Lee J, Cho J J Vet Sci. 2025; 26(1):e9.
PMID: 39901471 PMC: 11799094. DOI: 10.4142/jvs.24259.
Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches.
Leal A, Herreno-Pachon A, Benincore-Florez E, Karunathilaka A, Tomatsu S Int J Mol Sci. 2024; 25(5).
PMID: 38473704 PMC: 10931195. DOI: 10.3390/ijms25052456.